Parkinson, James

Parkinsonism, or Parkinson s disease, is named for James Parkinson who first described the disease back in 1817. It is nsnally a disease of the elderly characterized by a spectrnm of movement disorders involnntary movements, rigidity, slowness, and loss of balance. It may progress to mental impairment, including depression. This is basically the same spectrum of movement disorders sometimes seen in schizophrenia patients taking dopamine antagonists. This snggests that parkinsonism may reflect, in some manner, a deficit in dopamine activity. 

Parkinson IJ, Hammond SJ, James RH, Rogers NW (2007) High-temperature lithium isotope fractionation insights from lithium isotope diffusion in magmatic systems. Earth Planet Sci Lett 257 609-621... 

The classic publication in 1817 by James Parkinson defined the triad of distinguishing symptoms that bear his name this movement disorder is known as Parkinson s... 

Parkinsonism is an extrapyramidal motor disorder, characterized by akinesia, rigidity and tremor with secondary manifestations such as excessive salivation, seborrhoea, mood changes (especially depression) and in certain patients, liver damage has been reported. It was first described by James Parkinson in 1817. 

Parkinsonism is the collective name for a group of disorders that share similar clinical characteristics, including tremor, rigidity of the limbs or trunk, bradyki-nesia, and postural instability. The most well known of these disorders is Parkinson s disease, which was first described in 1817 by James Parkinson in Essay on the Shaking Palsy (70). Parkinson s disease is also known as primary or idiopathic Parkinson s disease. 

James JR, Nordberg A. 1995. Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders emphasis on Alzheimer s disease and Parkinson s disease. Behav Gen 25 149-159. 

Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM (1992) L-dopa withdrawal selectively impairs performance in tests of frontal lobe function in Parkinson s disease. Psychopharmacology 707 394-404. 

Owen AM, James M, Leigh PH, Summers BA, Marsden CD, Quinn NP, Lange KW, Robbins TW (1992) Fronto-striatal cognitive deficits at different stages of Parkinson s disease. Brain 775 1727-1751. 

James Parkinson (1755-1824), physician he described paralysis agitans in 1817. 

Factor SA, Weiner WJ. James Parkinson The man and the essay. In Factor SA, Weiner WJ, eds. Parkinson s Disease Diagnosis and Clinical Management. New York, Demos, 2002 1-18. 

Dr James Parkinson first described this disease in 1817 as paralysis agitans or the shaking palsy. Parkinson s disease is the second most common neurodegenerative disease after Alzheimer s disease, affecting 2% of the population over the age of 65. 

PD is the only neurodegenerative disorder we can symptomatically treat in a very specific and effective manner. Since the first description of the disease by James Parkinson in 1817, a number of procedures for handling this disease have been developed. 

FIGURE 240. Dr. James Woodhouse, Professor of Chemistry at the University of Pennsylvania, founded the Chemical Society of Philadelphia. He also had a profitable lecture series for which he sold his own chemical apparatus. He proclaimed it to he far superior and more economical than that of Guyton de Morveau in France. (From Parkinson, The Chemical Pocket-Book, 1802.)... 

J. Parkinson, Chemical Pocket-Book, James Humphreys, Philadelphia, 1802. 

Parkinson s disease or Paralysis agitans was first described as early as 1817 by James Parkinson, a London doctor, as consisting essentially of Involuntary tremulous motion with decreased muscular power in parts not in action and even when supported, with a propensity to bend the trunk forwards and to pass from a walking to a running pace, the senses and intellect being uninjured . 

Genetic engineering is used not only for drug development but also for treatment of specific patients. In 1998, James Thompson of the University of Wisconsin isolated human embryonic stem cells, called piuripotent, because they can produce specific types of cells within the living body. This insertion of genes into the patient s body may someday be used to treat diabetes, rheumatoid arthritis, cancer, Parkinson s, and other diseases. 

Parkinson s disease is a slowly progressive neurodegenerative disease of the CNS (central nervous system) first described in 1817 by James Parkinson. The incidence rates ranges from 4.5 to 21/100,000 individuals... 

John Mercer (Dean or Great Harwood, nr. Bolton, Lancs., 21 February 1791-Oakenshaw, Lancs., 30 November 1866), a calico-printer, discovered mercerising (1844), the use of potassium ferrocyanide and potash for the discharge of indigo (1848), the use of arsenates as a substitute for phosphates in dunging the manufacture of sodium stannite and stannate, stannous sulphate from tin and copper sulphate solution, Turkey-red oil, the solubility of cellulose in ammoniacal copper solution, and blue-print photography. He taught himself chemistry from a second-hand copy of the Chemical Pocket-Book of James Parkinson, of Hoxton Square, London (2 ed. 1801, 3 ed. 1803). ... 

Parkinson s disease was named by the French neurologist Jean Martin Charcot in recognition of the importance of London doctor James Parkinson who, in 1817, published a detailed medical description of "shaking palsy." In fact, the disease was known since antiquity, and it was previously described by the famous physician Galen in 175 c.e. 

---